124 related articles for article (PubMed ID: 22911202)
1. Topical aprepitant in clinical and experimental pruritus.
Wallengren J
Arch Dermatol; 2012 Aug; 148(8):957-9. PubMed ID: 22911202
[No Abstract] [Full Text] [Related]
2. Aprepitant against pruritus in patients with solid tumours.
Vincenzi B; Fratto ME; Santini D; Tonini G
Support Care Cancer; 2010 Sep; 18(9):1229-30. PubMed ID: 20544226
[No Abstract] [Full Text] [Related]
3. Aprepitant as an antipruritic agent?
Duval A; Dubertret L
N Engl J Med; 2009 Oct; 361(14):1415-6. PubMed ID: 19797294
[No Abstract] [Full Text] [Related]
4. Aprepitant for erlotinib-induced pruritus.
Vincenzi B; Tonini G; Santini D
N Engl J Med; 2010 Jul; 363(4):397-8. PubMed ID: 20660413
[No Abstract] [Full Text] [Related]
5. Topical non-peptide antagonists of sensory neurotransmitters substance P and CGRP do not modify patch test and prick test reactions: a vehicle-controlled, double-blind pilot study.
Wallengren J; Edvinsson L
Arch Dermatol Res; 2014 Jul; 306(5):505-9. PubMed ID: 24525842
[TBL] [Abstract][Full Text] [Related]
6. [Aprepitant and pruritus--comment].
Manasek V
Klin Onkol; 2012; 25(6):491-2. PubMed ID: 23346639
[No Abstract] [Full Text] [Related]
7. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
8. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Carides G; Elmer M; Schmidt C; Evans JK; Horgan KJ
J Clin Oncol; 2003 Nov; 21(22):4105-11. PubMed ID: 14559891
[TBL] [Abstract][Full Text] [Related]
9. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
10. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
Sankhala KK; Pandya DM; Sarantopoulos J; Soefje SA; Giles FJ; Chawla SP
Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1607-14. PubMed ID: 19929449
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting.
Gan TJ; Apfel CC; Kovac A; Philip BK; Singla N; Minkowitz H; Habib AS; Knighton J; Carides AD; Zhang H; Horgan KJ; Evans JK; Lawson FC;
Anesth Analg; 2007 May; 104(5):1082-9, tables of contents. PubMed ID: 17456656
[TBL] [Abstract][Full Text] [Related]
12. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma.
Booken N; Heck M; Nicolay JP; Klemke CD; Goerdt S; Utikal J
Br J Dermatol; 2011 Mar; 164(3):665-7. PubMed ID: 21039410
[No Abstract] [Full Text] [Related]
13. Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Ruhlmann CH; Herrstedt J
Expert Rev Anticancer Ther; 2012 Feb; 12(2):139-50. PubMed ID: 22316362
[TBL] [Abstract][Full Text] [Related]
14. Aprepitant: Evidence of its effectiveness in patients with refractory pruritus continues.
Torres T; Fernandes I; Selores M; Alves R; Lima M
J Am Acad Dermatol; 2012 Jan; 66(1):e14-5. PubMed ID: 22177649
[No Abstract] [Full Text] [Related]
15. More on aprepitant for erlotinib-induced pruritus.
Gerber PA; Buhren BA; Homey B
N Engl J Med; 2011 Feb; 364(5):486-7. PubMed ID: 21288112
[No Abstract] [Full Text] [Related]
16. Aprepitant (EMEND): the role of substance P in nausea and vomiting.
Prommer E
J Pain Palliat Care Pharmacother; 2005; 19(3):31-9. PubMed ID: 16219609
[TBL] [Abstract][Full Text] [Related]
17. A randomized, placebo-controlled, crossover, double-blind trial of the NK1 receptor antagonist aprepitant on gastrointestinal motor function in healthy humans.
Madsen JL; Fuglsang S
Aliment Pharmacol Ther; 2008 Apr; 27(7):609-15. PubMed ID: 18208572
[TBL] [Abstract][Full Text] [Related]
18. The influence of the opiate antagonist naloxone on experimental pruritus.
Fjellner B; Hägermark O
Acta Derm Venereol; 1984; 64(1):73-5. PubMed ID: 6203288
[TBL] [Abstract][Full Text] [Related]
19. [Prevention of nausea and vomiting. Aprepitant, the first therapeutic acting NK-1 receptor antagonist].
Nieber K; Schoppmeyer K
Pharm Unserer Zeit; 2007; 36(5):373-80. PubMed ID: 17722144
[No Abstract] [Full Text] [Related]
20. Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant.
Ohanyan T; Schoepke N; Eirefelt S; Hoey G; Koopmann W; Hawro T; Maurer M; Metz M
Acta Derm Venereol; 2018 Jan; 98(1):26-31. PubMed ID: 28853492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]